Global Pazopanib API Market Research Report 2024

Publication ID:

PB506248304

Publication Date:

June 21, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Specialty Chemicals [2]

Manufacturing (Chemicals) [3]

Chemicals [4]

Description:

Pazopanib is an anticancer medication that belongs to the class of drugs known as kinase inhibitors. It is primarily used for the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma.
API stands for Active Pharmaceutical Ingredient, which is the biologically active component in a drug product that produces the intended therapeutic effect. Pazopanib API refers to the pure form of pazopanib that is used as the active ingredient in the manufacturing of pazopanib-based medications.
Pazopanib API is typically produced through chemical synthesis, which involves multi-step processes to obtain the desired compound in its pure form. This pure active ingredient is then used as a starting material for formulating tablets, capsules, or other drug dosage forms.
The global Pazopanib API market was valued at US$ 1300 million in 2023 and is anticipated to reach US$ 2225.1 million by 2030, witnessing a CAGR of 7.9% during the forecast period 2024-2030.
The global pazopanib API market refers to the market for the active pharmaceutical ingredient (API) of pazopanib, a medication used for the treatment of certain types of cancer. Pazopanib is an oral, multi-kinase inhibitor that works by inhibiting the growth of blood vessels within tumors, thereby suppressing their progression.
The market for pazopanib API is driven by several factors, including the increasing incidence of cancer worldwide, the growing demand for targeted therapies, and advancements in pharmaceutical research and development. Pazopanib is primarily indicated for the treatment of advanced renal cell carcinoma (kidney cancer), as well as soft tissue sarcoma.
Geographically, the market for pazopanib API is global, with significant demand in regions such as North America, Europe, and Asia-Pacific. North America, particularly the United States, holds a prominent share due to a high prevalence of renal cell carcinoma, well-established healthcare infrastructure, and robust drug development capabilities. Europe is another significant market, driven by factors such as increasing awareness about targeted therapies and the presence of major pharmaceutical companies. Asia-Pacific is witnessing rapid growth, attributed to factors such as a rising incidence of cancer, improving healthcare infrastructure, and increasing investments in research and development.
Key players in the global pazopanib API market include pharmaceutical companies involved in API manufacturing, contract research organizations (CROs), and contract manufacturing organizations (CMOs). These companies focus on the development and production of high-quality pazopanib API, complying with regulatory standards and ensuring the availability of a reliable supply chain.
However, challenges in the pazopanib API market include potential side effects and adverse reactions associated with the medication, high costs of targeted therapies, and competition from generic alternatives. Additionally, the market dynamics for APIs are influenced by factors such as the patent expiration of branded drugs and the emergence of biosimilars.
In summary, the global pazopanib API market is driven by factors such as the increasing incidence of cancer, demand for targeted therapies, and advancements in pharmaceutical research. North America currently leads the market, but Asia-Pacific is witnessing rapid growth. Key players in the market continue to focus on the development and production of high-quality pazopanib API to meet the demand for cancer treatment and improve patient outcomes.
This report aims to provide a comprehensive presentation of the global market for Pazopanib API, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pazopanib API.
Report Scope
The Pazopanib API market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pazopanib API market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pazopanib API companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Tecoland
FCDA
BIOBERRY
Abcr
Dr. Reddys Laboratories
Pharmaffiliates
Jigs Chemical Limited
MuseChem
Hairuichem
AlchemyPharm
Wuhan Fortuna Chemical
Shanghai Pharmaceutical Group Co
Shijiazhuang Dingmin Pharmaceutical Sciences
CR Pharmaceutical Group
Guangzhou Baiyunshan Pharmaceutical Group
Segment by Type
Min Purity Less Than 98%
Min Purity 98%-99%
Min Purity More Than 99%
Segment by Application
Research
Pharmaceutical
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pazopanib API companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pazopanib API Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Min Purity Less Than 98%
1.2.3 Min Purity 98%-99%
1.2.4 Min Purity More Than 99%
1.3 Market by Application
1.3.1 Global Pazopanib API Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Research
1.3.3 Pharmaceutical
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pazopanib API Market Perspective (2019-2030)
2.2 Pazopanib API Growth Trends by Region
2.2.1 Global Pazopanib API Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Pazopanib API Historic Market Size by Region (2019-2024)
2.2.3 Pazopanib API Forecasted Market Size by Region (2025-2030)
2.3 Pazopanib API Market Dynamics
2.3.1 Pazopanib API Industry Trends
2.3.2 Pazopanib API Market Drivers
2.3.3 Pazopanib API Market Challenges
2.3.4 Pazopanib API Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pazopanib API Players by Revenue
3.1.1 Global Top Pazopanib API Players by Revenue (2019-2024)
3.1.2 Global Pazopanib API Revenue Market Share by Players (2019-2024)
3.2 Global Pazopanib API Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pazopanib API Revenue
3.4 Global Pazopanib API Market Concentration Ratio
3.4.1 Global Pazopanib API Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pazopanib API Revenue in 2023
3.5 Pazopanib API Key Players Head office and Area Served
3.6 Key Players Pazopanib API Product Solution and Service
3.7 Date of Enter into Pazopanib API Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pazopanib API Breakdown Data by Type
4.1 Global Pazopanib API Historic Market Size by Type (2019-2024)
4.2 Global Pazopanib API Forecasted Market Size by Type (2025-2030)
5 Pazopanib API Breakdown Data by Application
5.1 Global Pazopanib API Historic Market Size by Application (2019-2024)
5.2 Global Pazopanib API Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Pazopanib API Market Size (2019-2030)
6.2 North America Pazopanib API Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Pazopanib API Market Size by Country (2019-2024)
6.4 North America Pazopanib API Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pazopanib API Market Size (2019-2030)
7.2 Europe Pazopanib API Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Pazopanib API Market Size by Country (2019-2024)
7.4 Europe Pazopanib API Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pazopanib API Market Size (2019-2030)
8.2 Asia-Pacific Pazopanib API Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Pazopanib API Market Size by Region (2019-2024)
8.4 Asia-Pacific Pazopanib API Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pazopanib API Market Size (2019-2030)
9.2 Latin America Pazopanib API Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Pazopanib API Market Size by Country (2019-2024)
9.4 Latin America Pazopanib API Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pazopanib API Market Size (2019-2030)
10.2 Middle East & Africa Pazopanib API Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Pazopanib API Market Size by Country (2019-2024)
10.4 Middle East & Africa Pazopanib API Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Tecoland
11.1.1 Tecoland Company Detail
11.1.2 Tecoland Business Overview
11.1.3 Tecoland Pazopanib API Introduction
11.1.4 Tecoland Revenue in Pazopanib API Business (2019-2024)
11.1.5 Tecoland Recent Development
11.2 FCDA
11.2.1 FCDA Company Detail
11.2.2 FCDA Business Overview
11.2.3 FCDA Pazopanib API Introduction
11.2.4 FCDA Revenue in Pazopanib API Business (2019-2024)
11.2.5 FCDA Recent Development
11.3 BIOBERRY
11.3.1 BIOBERRY Company Detail
11.3.2 BIOBERRY Business Overview
11.3.3 BIOBERRY Pazopanib API Introduction
11.3.4 BIOBERRY Revenue in Pazopanib API Business (2019-2024)
11.3.5 BIOBERRY Recent Development
11.4 Abcr
11.4.1 Abcr Company Detail
11.4.2 Abcr Business Overview
11.4.3 Abcr Pazopanib API Introduction
11.4.4 Abcr Revenue in Pazopanib API Business (2019-2024)
11.4.5 Abcr Recent Development
11.5 Dr. Reddys Laboratories
11.5.1 Dr. Reddys Laboratories Company Detail
11.5.2 Dr. Reddys Laboratories Business Overview
11.5.3 Dr. Reddys Laboratories Pazopanib API Introduction
11.5.4 Dr. Reddys Laboratories Revenue in Pazopanib API Business (2019-2024)
11.5.5 Dr. Reddys Laboratories Recent Development
11.6 Pharmaffiliates
11.6.1 Pharmaffiliates Company Detail
11.6.2 Pharmaffiliates Business Overview
11.6.3 Pharmaffiliates Pazopanib API Introduction
11.6.4 Pharmaffiliates Revenue in Pazopanib API Business (2019-2024)
11.6.5 Pharmaffiliates Recent Development
11.7 Jigs Chemical Limited
11.7.1 Jigs Chemical Limited Company Detail
11.7.2 Jigs Chemical Limited Business Overview
11.7.3 Jigs Chemical Limited Pazopanib API Introduction
11.7.4 Jigs Chemical Limited Revenue in Pazopanib API Business (2019-2024)
11.7.5 Jigs Chemical Limited Recent Development
11.8 MuseChem
11.8.1 MuseChem Company Detail
11.8.2 MuseChem Business Overview
11.8.3 MuseChem Pazopanib API Introduction
11.8.4 MuseChem Revenue in Pazopanib API Business (2019-2024)
11.8.5 MuseChem Recent Development
11.9 Hairuichem
11.9.1 Hairuichem Company Detail
11.9.2 Hairuichem Business Overview
11.9.3 Hairuichem Pazopanib API Introduction
11.9.4 Hairuichem Revenue in Pazopanib API Business (2019-2024)
11.9.5 Hairuichem Recent Development
11.10 AlchemyPharm
11.10.1 AlchemyPharm Company Detail
11.10.2 AlchemyPharm Business Overview
11.10.3 AlchemyPharm Pazopanib API Introduction
11.10.4 AlchemyPharm Revenue in Pazopanib API Business (2019-2024)
11.10.5 AlchemyPharm Recent Development
11.11 Wuhan Fortuna Chemical
11.11.1 Wuhan Fortuna Chemical Company Detail
11.11.2 Wuhan Fortuna Chemical Business Overview
11.11.3 Wuhan Fortuna Chemical Pazopanib API Introduction
11.11.4 Wuhan Fortuna Chemical Revenue in Pazopanib API Business (2019-2024)
11.11.5 Wuhan Fortuna Chemical Recent Development
11.12 Shanghai Pharmaceutical Group Co
11.12.1 Shanghai Pharmaceutical Group Co Company Detail
11.12.2 Shanghai Pharmaceutical Group Co Business Overview
11.12.3 Shanghai Pharmaceutical Group Co Pazopanib API Introduction
11.12.4 Shanghai Pharmaceutical Group Co Revenue in Pazopanib API Business (2019-2024)
11.12.5 Shanghai Pharmaceutical Group Co Recent Development
11.13 Shijiazhuang Dingmin Pharmaceutical Sciences
11.13.1 Shijiazhuang Dingmin Pharmaceutical Sciences Company Detail
11.13.2 Shijiazhuang Dingmin Pharmaceutical Sciences Business Overview
11.13.3 Shijiazhuang Dingmin Pharmaceutical Sciences Pazopanib API Introduction
11.13.4 Shijiazhuang Dingmin Pharmaceutical Sciences Revenue in Pazopanib API Business (2019-2024)
11.13.5 Shijiazhuang Dingmin Pharmaceutical Sciences Recent Development
11.14 CR Pharmaceutical Group
11.14.1 CR Pharmaceutical Group Company Detail
11.14.2 CR Pharmaceutical Group Business Overview
11.14.3 CR Pharmaceutical Group Pazopanib API Introduction
11.14.4 CR Pharmaceutical Group Revenue in Pazopanib API Business (2019-2024)
11.14.5 CR Pharmaceutical Group Recent Development
11.15 Guangzhou Baiyunshan Pharmaceutical Group
11.15.1 Guangzhou Baiyunshan Pharmaceutical Group Company Detail
11.15.2 Guangzhou Baiyunshan Pharmaceutical Group Business Overview
11.15.3 Guangzhou Baiyunshan Pharmaceutical Group Pazopanib API Introduction
11.15.4 Guangzhou Baiyunshan Pharmaceutical Group Revenue in Pazopanib API Business (2019-2024)
11.15.5 Guangzhou Baiyunshan Pharmaceutical Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Tecoland
FCDA
BIOBERRY
Abcr
Dr. Reddys Laboratories
Pharmaffiliates
Jigs Chemical Limited
MuseChem
Hairuichem
AlchemyPharm
Wuhan Fortuna Chemical
Shanghai Pharmaceutical Group Co
Shijiazhuang Dingmin Pharmaceutical Sciences
CR Pharmaceutical Group
Guangzhou Baiyunshan Pharmaceutical Group

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂